July, 2018
Partager Partager Partager Partager
AURP Delegation visit Genopole
Association of University Research Parks at GENOPOLE for an I2RP

It was a pleasure and a privilege for us to host 15 delegates from the Association of University Research Parks (AURP) who chose Genopole to organise the European première of the so-called I2RP events (Insights into Research Parks).
More than 170 research parks and related stakeholders are members of AURP all around the world. The objective of AURP is to foster innovation, commercialization and economic growth in a global economy through university, industry and government partnerships.

The program opened with a full day at Genopole, the first French biocluster dedicated to R&D in genomics and biotechnology, on Wednesday June 20, starting with a presentation by our Director of International Affairs and MC, Denis Gauvreau, who covered the history of our biocluster, described the incubator and accelerator services provided to start-up companies moving on our site, as well as explained the development of Genopole’s current 19 public research laboratories and 25 technology platforms. The day at Genopole also included a visit of France’s power house in genomic sequencing with Genoscope presenting TARA’s sequencing program of ocean microorganisms, followed by a presentation by Philippe Marlière on future synthetic biology developments, as well as visits of YposKesi’s facilities for the production of clinical lots for gene therapy trials, and of I-STEM’s research laboratories in cell therapy. To quote the President of AURP, Mason Ailstock, the day at Genopole had concretely put the “gene” into “Genopole”.

On Thursday June 21, AURP delegates were hosted by the University Paris-Saclay (UPSaclay), with President Gilles Bloch kicking off a full day of presentations on, and tour of, the site that is considered as one of the top 8 most important R&D&I clusters currently under development in the world. On Friday June 22, AURP delegates also met with France’s Banque Publique d’Investissement (BPI) and Paris Region Entreprises (PRE) that both spoke of Paris’ competitive advantages and of current initiatives in pushing innovation.

We were impressed by the quality of the exchanges during all the proceedings, with AURP delegates bringing a very friendly atmosphere at evening dinners in a Parisian typical restaurant and at the Department of Essonne’s Château de Chamarande - all under glorious weather. I am also happy to report that representatives of the French stakeholders met and some AURP members who visited Genopole have already followed up with further discussions. We look forward to more exchanges with other AURP members, in working towards building stronger links between France and North America. Many thanks again to the AURP delegates for their visit. A bientôt, we hope !

Jean-Marc Grognet, CEO


BIOLAKE Partnership

Genopole’s CEO and Chairman, Jean-Marc Grognet and Marianne Duranton, were part of a delegation to Wuhan led by the President of the Department of Essonne, François Durovray, to meet a number of local institutions and officials. Genopole signed on this occasion a partnership agreement with the biocluster Biolake.
Genopole is keen on exploring links with China and there is increasing interest from the companies in the biocluster to develop Chinese business contacts, as witnessed by their participation in a workshop organised in April on “Developing Business in China: It’s Possible”.

Biolake partnership
The agreement between Genopole and Biolake is targeting in priority the establishment of a first collaborative project that will bring together private or public stakeholders from both parties. The objective is also to allow the bioclusters to connect more closely on a number of practical matters (e.g., exchange of good practices, support to start-ups, access to technology platforms). Parties have started working on candidate projects around which to scaffold the Sino-French connections, and exchange site visits are planned over the next 8 months between Wuhan and Evry.

Global Bioenergies to Take Part in Three Large H2020 Projects Gathering Numerous Academic Institutions and Industrialists From All Over Europe
Global Bioenergies
Global Bioenergies (Euronext Growth: ALGBE) has recently announced having been selected in three additional Horizon 2020 projects funded by the European Union, and will receive for this purpose about €2m in grants over 4 years. These projects reinforce Global Bioenergies’ strategy of feedstock diversification in order to continue improving the economics and the environmental impact of its isobutene process.

Read more {...} read more

PEP-Therapy, Institut Curie and Gustave Roussy Obtain 2,9 M€ to Develop a Novel Peptide in Oncology

PEP-Therapy is joining forces with Institut Curie and Institut Gustave Roussy for the Clever-Peptide project that targets the development of its innovative anti-cancer peptide for use in the treatment of triple-negative breast cancer along with a companion biomarker predictive of treatment efficacy. Institut Curie and Institut Gustave Roussy are leading comprehensive cancer centers in Europe and they will combine their complementary skills with PEP-Therapy for the design of innovative peptides, translational research, pharmaceutical development and oncology clinical trials.
The consortium will receive a total of 2,9 M€ funding from Bpifrance and the Ile-de-France Region.

Read more {...} read more
Genopole’s Support Programs for Scientists

Genopole has attracted 107 scientists to the biocluster since its creation with the two following support programs :
Booster Genopole - The " Post-Doctoral Allocations " have now benefited 80 French scientists who were working abroad and have since returned to Genopole, to pursue their career in companies and in research laboratories.

- The " Atiges " have provided 27 scientists with the financial support necessary to create a new research team within an existing research laboratory at Genopole.
Read more {...} read more

World Records Set at BIO 2018

With 18,000+ attendees, we understand that Guinness World Records were set at BIO-2018, for Largest Partnering Event with nearly 47,000 One-on-One meetings that involved more than 7,900 delegates from 3,900 companies. It was also a very busy BIO this year for Genopole, with lots of circulation at our stand that was well in evidence on France’s booth, a presentation of our cluster at the Global Innovation Hub, a series of One-on-One partnering meetings, as well as a number of meetings with representatives of research parks and bioclusters from the US, China, Korea, Canada, Brazil and other European countries.
Bio 2018 - Genopole
It is noteworthy mentioning that the number of talks, panels, and presentations on gene and cell therapy as well as on precision medicine are now much in evidence at BIO, and occupying increased space in the program from one year to another.
With the “gene” as a prefix in its name, one can only measure our founders’ vision who 20 years ago this year gave life to Genopole.
Read more {...} read more
Genopole ŕ VivaTech - B. Sacy et Q. Bernard
Genopole Companies at Vivatech 2018 in Paris

Vivatech gathered a large crowd of participants in Paris on May 24-26, 2018 for its annual innovation and entrepreneurship meeting.

Three of Genopole’s companies were on site to promote their products : Spiris, co-founded by Bernard Sacy (left picture), that specialises in high-scale production of spirulin, Bioshield, co-founded by Quentin Bernard, that develops antibiofilm products for industrial surfaces, Glowee, that develops bioluminescent systems.

Nebraska's Biotech Connector at Genopole

Representatives of Nebraska’s Biotech Connector - Eric Zeece, who is Innovation Manager of Invest Nebraska Corporation, and Cobus Block, who is International Business Manager of the Department of Economic Development of the State of Nebraska - visited Genopole on May 23-24, 2018, specifically to discuss collaborative developments in synthetic biology.
Nebraska's Biotech Connector @ Genopole
Read more {...} read more
Brussels Hong-Kong Representatives at Genopole
Hong-kong Economic and trande office @ Genopole
Representatives of Hong Kong's Economic and Trade Office in Brussels visited Genopole on May 29, 2018, to discuss important R&D policy developments by Hong-Kong, as well as to prepare upcoming visits to France by Hong Kong's leading innovation stakeholders.
Read more {...} read more

Genopole to Assist in the Development of the Grand Paris Sud Sport Cluster

The Agglomeration Grand Paris Sud and the Department of Essonne have announced that they are acting as promoters for the establishment of the Grand Paris Sud Sport Cluster that will be located on the grounds of the old Ris-Orangis hippodrome.
CLuster Sport - ŠLionel Antoni
This original and ambitious project was actually inspired by Genopole’s biocluster model that federates private and public stakeholders and is also founded on the triangle of education, research and entreprises. Genopole was asked to provide support and expertise relating to genomic research directions and for the creation of a mixed research unit to be established at the University of Evry on sports and health.
Read more {...} read more
Mark the date in your calendar: November 13, 2018
Living Innovation Today and Tomorrow

  Genopole 20 years
  Genopole will be celebrating its 20th birthday by hosting a roster of leading scientists and innovation stakeholders. The prestigious Eric Green (Director of the US National Human Genome Research Institute) will kick off the proceedings with his 2020 vision for human genomics and precision medicine.
International status speakers will present their views on human genome engineering and genetic disorders, big data, deep learning and AI in the future of medicine. Others will debate on the emergence of synthetic biology and genome engineering in industrial biotechnology and the perspective for the bioeconomy.
International companies are supporting innovation through dedicated sponsorship packages.

If you want to participate or engage your company on these topics, contact us at

  Nicole CHEMALI
+33 1 60 87 83 11 -
+33 6 30 55 64 37 -
  For additional information, write to